Evidence map›Paper›PMID 35617369›Full record

ArticlePloS one2022

Circulating microRNA-122 in HCV cirrhotic patients with high frequency of genotype 3.

Amin Ullah, Xiaojie Yu, Margarete Odenthal, Sonja Meemboor, Bashir Ahmad, Irshad Ur Rehman, Jamshaid Ahmad, Qurban Ali, Tariq Nadeem

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. MicroRNA-122 as a regulator and biomarker of liver disease.Journal of molecular medicine (Berlin, Germany) · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Biomarkers in Detection of Hepatitis C Virus Infection.Pathogens (Basel, Switzerland) · 2024
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Amin UllahCentre of Biotechnology & Microbiology (COBAM), University of Peshawar, Peshawar, Pakistan.
Xiaojie YuCentre for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Margarete OdenthalCentre for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Sonja MeemboorCentre for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Bashir AhmadCentre of Biotechnology & Microbiology (COBAM), University of Peshawar, Peshawar, Pakistan.
Irshad Ur RehmanCentre of Biotechnology & Microbiology (COBAM), University of Peshawar, Peshawar, Pakistan.
Jamshaid AhmadCentre of Biotechnology & Microbiology (COBAM), University of Peshawar, Peshawar, Pakistan.
Qurban AliInstitute of Molecular Biology and Biotechnology, University of Lahore, Lahore, Pakistan.ORCID 0000-0002-3160-4830
Tariq NadeemNational Center of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan.
University of Cologne · DEUniversity of Peshawar · PKUniversity of Lahore · PKUniversity of the Punjab · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA-122 (miR-122) is a liver abundant microRNA that is released upon liver injury. In the present study, we investigated the circulating miR-122 profiles in a Pakistani patients´ cohort with HCV chronic liver disease that was mainly based on HCV genotype 3 infections. From 222 patients with chronic HCV liver disease, classified as mild, moderate, or severe, serum samples were collected. Cell-free RNA was isolated and used for miR-122 quantification by qPCR. More than 60% of 222 patients were infected with HCV genotype 3. ALT values and HCV viral load showed no correlation with the HCV genotype. Circulating miR-122 levels were significantly upregulated in patients with cirrhosis. Notably, HCV patients with mild cirrhosis showed the most marked increase in serum miR-122 levels (p = 0.0001). Furthermore, we proved a positive correlation (r = 0.46) of miR-122 with the ALT values in patients with mild cirrhosis. Importantly, our data of increased miR-122 levels in serum samples obtained from a patient cohort with a high prevalence of chronic genotype 3 HCV infection confirmed the previous findings collected from cohorts with a high prevalence of genotype 1. Therefore, we suggest that miR-122 increase after HCV infection does not depend on the HCV genotype. In conclusion, our findings confirm that serum miR-122 levels are significantly upregulated in the HCV cirrhotic patients serving in particular as a biomarker for the non-advanced stages of cirrhosis, independently of the HCV genotype.

Indexed as

Circulating MicroRNAHepatitis CMicroRNAsGenotypeHepacivirusHumansLiver CirrhosisCirculating MicroRNAMicroRNAsMIRN122 microRNA, human

Identifiers

PMID35617369
PMCPMC9135289
OpenAlexW4281654102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.